Craig-Hallum analyst Jeff Van Rhee raised the firm’s price target on Cellebrite to $16 from $14 and keeps a Buy rating on the shares following the company’s first analyst day. The firm says that for a first analyst day, the event and team were surprisingly crisp. Craig-Hallum continues to be impressed by the caliber of the talent and depth of bench.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite to host investor day
- Cellebrite appoints David Gee as CMO
- Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership
- Cellebrite Files its 2023 Annual Report on Form 20-F
- Cellebrite Revolutionizes Data Collection with Ground-breaking SaaS Solution, Integral Part of Company’s Case-to-Closure Platform
